Cargando…

Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice

BACKGROUND: Helminth infections and their components have been shown to have a protective effect on autoimmune diseases. The isolated purified protein from Schisotosoma japonicum and its potential therapeutic effect on trinitrobenzene sulfonic acid (TNBS)-induced colitis could provide an alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shushu, Xie, Yuanyuan, Yang, Xiaodi, Wang, Xuesong, Yan, Ke, Zhong, Zhengrong, Wang, Xiaowei, Xu, Yuanhong, Zhang, Yi, Liu, Fang, Shen, Jilong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700642/
https://www.ncbi.nlm.nih.gov/pubmed/26728323
http://dx.doi.org/10.1186/s13071-015-1288-1
_version_ 1782408354486812672
author Wang, Shushu
Xie, Yuanyuan
Yang, Xiaodi
Wang, Xuesong
Yan, Ke
Zhong, Zhengrong
Wang, Xiaowei
Xu, Yuanhong
Zhang, Yi
Liu, Fang
Shen, Jilong
author_facet Wang, Shushu
Xie, Yuanyuan
Yang, Xiaodi
Wang, Xuesong
Yan, Ke
Zhong, Zhengrong
Wang, Xiaowei
Xu, Yuanhong
Zhang, Yi
Liu, Fang
Shen, Jilong
author_sort Wang, Shushu
collection PubMed
description BACKGROUND: Helminth infections and their components have been shown to have a protective effect on autoimmune diseases. The isolated purified protein from Schisotosoma japonicum and its potential therapeutic effect on trinitrobenzene sulfonic acid (TNBS)-induced colitis could provide an alternative way to treat inflammatory bowel disease (IBDs). METHODS: Colitis was induced in Balb/c mice by rectal administration of 2.5 % TNBS, followed by intraperitoneal injection of rSjcystatin 50 μg at 6 h and 24 h afterwards. The inflammation was monitored by recording weight change, stool character and bleeding, colon length, macroscopic score (MAO), microscopic score (MIO), myeloperoxidase activity (MPO) and disease activity index (DAI). The potential underlying mechanism was investigated by examining cytokine profiles including Th1 (IFNγ), Th2 (IL-4), Th17 (IL-17A) and Treg subsets from lymphocytes of spleen, mesenteric lymph nodes (MLN) and intestinal lamina propria mononuclear cells (LPMCs) by flow cytometry. The mRNA relative expressions of the cytokines in splenocytes and MLN were analysed by quantitative real time reverse-transcriptase polymerase chain reaction (qRT-PCR). Simultaneously, the concentrations of the cytokines in the colon homogenate supernatants were tested by enzyme-linked immunosorbent assay (ELISA) and key transcription factors were detected by Western blotting. RESULTS: Administration of rSjcystatin significantly reduced inflammatory parameters and ameliorated the severity of the TNBS-induced colitis through decreasing IFNγ in three organs and lifting the level of IL-4, IL-13, IL-10, and TGF-β in the colon tissues, with uptrending Tregs in the MLN and LPMC. CONCLUSION: The findings provide evidence that rSjcystatin has a therapeutic potential for diminishing colitis inflammation in Balb/c mice. The immunological mechanism may involve the down-regulation of Th1 response and up-regulation of Th2 and Tregs in the MLN and colon.
format Online
Article
Text
id pubmed-4700642
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47006422016-01-06 Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice Wang, Shushu Xie, Yuanyuan Yang, Xiaodi Wang, Xuesong Yan, Ke Zhong, Zhengrong Wang, Xiaowei Xu, Yuanhong Zhang, Yi Liu, Fang Shen, Jilong Parasit Vectors Research BACKGROUND: Helminth infections and their components have been shown to have a protective effect on autoimmune diseases. The isolated purified protein from Schisotosoma japonicum and its potential therapeutic effect on trinitrobenzene sulfonic acid (TNBS)-induced colitis could provide an alternative way to treat inflammatory bowel disease (IBDs). METHODS: Colitis was induced in Balb/c mice by rectal administration of 2.5 % TNBS, followed by intraperitoneal injection of rSjcystatin 50 μg at 6 h and 24 h afterwards. The inflammation was monitored by recording weight change, stool character and bleeding, colon length, macroscopic score (MAO), microscopic score (MIO), myeloperoxidase activity (MPO) and disease activity index (DAI). The potential underlying mechanism was investigated by examining cytokine profiles including Th1 (IFNγ), Th2 (IL-4), Th17 (IL-17A) and Treg subsets from lymphocytes of spleen, mesenteric lymph nodes (MLN) and intestinal lamina propria mononuclear cells (LPMCs) by flow cytometry. The mRNA relative expressions of the cytokines in splenocytes and MLN were analysed by quantitative real time reverse-transcriptase polymerase chain reaction (qRT-PCR). Simultaneously, the concentrations of the cytokines in the colon homogenate supernatants were tested by enzyme-linked immunosorbent assay (ELISA) and key transcription factors were detected by Western blotting. RESULTS: Administration of rSjcystatin significantly reduced inflammatory parameters and ameliorated the severity of the TNBS-induced colitis through decreasing IFNγ in three organs and lifting the level of IL-4, IL-13, IL-10, and TGF-β in the colon tissues, with uptrending Tregs in the MLN and LPMC. CONCLUSION: The findings provide evidence that rSjcystatin has a therapeutic potential for diminishing colitis inflammation in Balb/c mice. The immunological mechanism may involve the down-regulation of Th1 response and up-regulation of Th2 and Tregs in the MLN and colon. BioMed Central 2016-01-04 /pmc/articles/PMC4700642/ /pubmed/26728323 http://dx.doi.org/10.1186/s13071-015-1288-1 Text en © Wang et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wang, Shushu
Xie, Yuanyuan
Yang, Xiaodi
Wang, Xuesong
Yan, Ke
Zhong, Zhengrong
Wang, Xiaowei
Xu, Yuanhong
Zhang, Yi
Liu, Fang
Shen, Jilong
Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice
title Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice
title_full Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice
title_fullStr Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice
title_full_unstemmed Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice
title_short Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice
title_sort therapeutic potential of recombinant cystatin from schistosoma japonicum in tnbs-induced experimental colitis of mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700642/
https://www.ncbi.nlm.nih.gov/pubmed/26728323
http://dx.doi.org/10.1186/s13071-015-1288-1
work_keys_str_mv AT wangshushu therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT xieyuanyuan therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT yangxiaodi therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT wangxuesong therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT yanke therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT zhongzhengrong therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT wangxiaowei therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT xuyuanhong therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT zhangyi therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT liufang therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice
AT shenjilong therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice